Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults

Gautam Baheti, Jennifer R. King, Edward P. Acosta, Courtney V Fletcher

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

INTRODUCTION: There is limited pediatric information on the complex relationships among the dose of tenofovir disoproxil fumarate (TDF), plasma concentrations of tenofovir (TFV), and intracellular TFV diphosphate (TFV-DP) concentrations. Our objectives were to describe TFV-DP pharmacokinetics in children and adolescents and investigate the effect of age on TFV and TFV-DP concentrations. METHODS: TFV-DP pharmacokinetics were determined in 47 children and adolescents. TFV and TFV-DP were quantified with validated liquid chromatography/tandem mass spectrometry methods. Data were pooled with other studies in HIV-infected adults (N=55). Nonlinear mixed effects modeling was used to develop the population model and explore the influence of covariates on TFV. A two-compartment model, partitioned for slow and fast absorbers by age, with weight allometrically scaled for children and adolescents, best described TFV pharmacokinetics. An indirect stimulation of response model best described TFV-DP formation. RESULTS: Apparent oral TFV clearance was significantly faster in patients less than 25 versus 25 years or more. The most significant covariate on apparent TFV oral clearance and central distribution volume was creatinine clearance. The TFV plasma concentration producing 50% of maximal TFV-DP concentrations was almost two-fold lower in patients less than 25 versus 25 years or more. The estimated intracellular TFV-DP half-life for these groups was 70 and 87h, respectively. CONCLUSION: These data demonstrate that children and adolescents receiving standard TDF dosing of 300mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations. This age-related difference appears to arise from an increased sensitivity to formation of TFV-DP.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalAIDS
Volume27
Issue number2
DOIs
StatePublished - Jan 14 2013

Fingerprint

Tenofovir
HIV-1

Keywords

  • age difference
  • antiretroviral therapy
  • nucleoside reverse transcriptase inhibitor
  • tenofovir
  • tenofovir diphosphate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. / Baheti, Gautam; King, Jennifer R.; Acosta, Edward P.; Fletcher, Courtney V.

In: AIDS, Vol. 27, No. 2, 14.01.2013, p. 221-225.

Research output: Contribution to journalArticle

@article{b9337eb7033049ad8e1da7d9f9a43f4e,
title = "Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults",
abstract = "INTRODUCTION: There is limited pediatric information on the complex relationships among the dose of tenofovir disoproxil fumarate (TDF), plasma concentrations of tenofovir (TFV), and intracellular TFV diphosphate (TFV-DP) concentrations. Our objectives were to describe TFV-DP pharmacokinetics in children and adolescents and investigate the effect of age on TFV and TFV-DP concentrations. METHODS: TFV-DP pharmacokinetics were determined in 47 children and adolescents. TFV and TFV-DP were quantified with validated liquid chromatography/tandem mass spectrometry methods. Data were pooled with other studies in HIV-infected adults (N=55). Nonlinear mixed effects modeling was used to develop the population model and explore the influence of covariates on TFV. A two-compartment model, partitioned for slow and fast absorbers by age, with weight allometrically scaled for children and adolescents, best described TFV pharmacokinetics. An indirect stimulation of response model best described TFV-DP formation. RESULTS: Apparent oral TFV clearance was significantly faster in patients less than 25 versus 25 years or more. The most significant covariate on apparent TFV oral clearance and central distribution volume was creatinine clearance. The TFV plasma concentration producing 50{\%} of maximal TFV-DP concentrations was almost two-fold lower in patients less than 25 versus 25 years or more. The estimated intracellular TFV-DP half-life for these groups was 70 and 87h, respectively. CONCLUSION: These data demonstrate that children and adolescents receiving standard TDF dosing of 300mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations. This age-related difference appears to arise from an increased sensitivity to formation of TFV-DP.",
keywords = "age difference, antiretroviral therapy, nucleoside reverse transcriptase inhibitor, tenofovir, tenofovir diphosphate",
author = "Gautam Baheti and King, {Jennifer R.} and Acosta, {Edward P.} and Fletcher, {Courtney V}",
year = "2013",
month = "1",
day = "14",
doi = "10.1097/QAD.0b013e32835a9a2d",
language = "English (US)",
volume = "27",
pages = "221--225",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults

AU - Baheti, Gautam

AU - King, Jennifer R.

AU - Acosta, Edward P.

AU - Fletcher, Courtney V

PY - 2013/1/14

Y1 - 2013/1/14

N2 - INTRODUCTION: There is limited pediatric information on the complex relationships among the dose of tenofovir disoproxil fumarate (TDF), plasma concentrations of tenofovir (TFV), and intracellular TFV diphosphate (TFV-DP) concentrations. Our objectives were to describe TFV-DP pharmacokinetics in children and adolescents and investigate the effect of age on TFV and TFV-DP concentrations. METHODS: TFV-DP pharmacokinetics were determined in 47 children and adolescents. TFV and TFV-DP were quantified with validated liquid chromatography/tandem mass spectrometry methods. Data were pooled with other studies in HIV-infected adults (N=55). Nonlinear mixed effects modeling was used to develop the population model and explore the influence of covariates on TFV. A two-compartment model, partitioned for slow and fast absorbers by age, with weight allometrically scaled for children and adolescents, best described TFV pharmacokinetics. An indirect stimulation of response model best described TFV-DP formation. RESULTS: Apparent oral TFV clearance was significantly faster in patients less than 25 versus 25 years or more. The most significant covariate on apparent TFV oral clearance and central distribution volume was creatinine clearance. The TFV plasma concentration producing 50% of maximal TFV-DP concentrations was almost two-fold lower in patients less than 25 versus 25 years or more. The estimated intracellular TFV-DP half-life for these groups was 70 and 87h, respectively. CONCLUSION: These data demonstrate that children and adolescents receiving standard TDF dosing of 300mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations. This age-related difference appears to arise from an increased sensitivity to formation of TFV-DP.

AB - INTRODUCTION: There is limited pediatric information on the complex relationships among the dose of tenofovir disoproxil fumarate (TDF), plasma concentrations of tenofovir (TFV), and intracellular TFV diphosphate (TFV-DP) concentrations. Our objectives were to describe TFV-DP pharmacokinetics in children and adolescents and investigate the effect of age on TFV and TFV-DP concentrations. METHODS: TFV-DP pharmacokinetics were determined in 47 children and adolescents. TFV and TFV-DP were quantified with validated liquid chromatography/tandem mass spectrometry methods. Data were pooled with other studies in HIV-infected adults (N=55). Nonlinear mixed effects modeling was used to develop the population model and explore the influence of covariates on TFV. A two-compartment model, partitioned for slow and fast absorbers by age, with weight allometrically scaled for children and adolescents, best described TFV pharmacokinetics. An indirect stimulation of response model best described TFV-DP formation. RESULTS: Apparent oral TFV clearance was significantly faster in patients less than 25 versus 25 years or more. The most significant covariate on apparent TFV oral clearance and central distribution volume was creatinine clearance. The TFV plasma concentration producing 50% of maximal TFV-DP concentrations was almost two-fold lower in patients less than 25 versus 25 years or more. The estimated intracellular TFV-DP half-life for these groups was 70 and 87h, respectively. CONCLUSION: These data demonstrate that children and adolescents receiving standard TDF dosing of 300mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations. This age-related difference appears to arise from an increased sensitivity to formation of TFV-DP.

KW - age difference

KW - antiretroviral therapy

KW - nucleoside reverse transcriptase inhibitor

KW - tenofovir

KW - tenofovir diphosphate

UR - http://www.scopus.com/inward/record.url?scp=84872387593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872387593&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835a9a2d

DO - 10.1097/QAD.0b013e32835a9a2d

M3 - Article

C2 - 23032419

AN - SCOPUS:84872387593

VL - 27

SP - 221

EP - 225

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -